N. Jane Taylor1, Nina Tunariu2, J James Stirling1, David J. Collins2, Paul Nathan3, James A. d'Arcy2, Mei-Lin W. Ah-See, Andreas Makris, Ian Judson4, Martin O. Leach2, Dow-Mu Koh2, Anwar R. Padhani1
1Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK; 2CR-UK Clinical MR Research Group, Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK; 3Oncology Dept, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK; 4Phase I Clinical Trials Unit, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
An evaluation of whether non-enhancing (NE) pixels should be included in DCE-MRI analyses of therapy response was performed, by comparing data from a breast cancer cohort receiving chemotherapy with a phase I cohort of mixed solid tumours receiving a combination of vascular disruptive and antiangiogenic agents. Our analysis shows that increasing numbers of NE pixels is a